Recombinant Thymidine Phosphorylase antibody (full length)

Catalog No. ABIN7879143

The Mouse Monoclonal anti-Thymidine Phosphorylase antibody is suitable to detect Thymidine Phosphorylase in samples from Human. It has been validated for WB and IHC (p).

Quick Overview for Recombinant Thymidine Phosphorylase antibody (full length) (ABIN7879143)

Target: Thymidine Phosphorylase (TYMP)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This Thymidine Phosphorylase antibody is un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Grade: Carrier-free

Clone: RTYMP-3444

Product Details anti-Thymidine Phosphorylase Antibody

Binding Specificity: full length

Purpose: Recombinant PD-ECGF Antibody / Thymidine Phosphorylase (azide and preservative free)

Purification: Protein G affinity chromatography

Immunogen: Recombinant full-length human protein was used as the immunogen for the recombinant PD-ECGF antibody.

Isotype: IgG1, kappa

Application Details

Application Notes: Optimal dilution of the recombinant PD-ECGF antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Preservative: Azide free

Storage: 4 °C,-20 °C

Storage Comment: Store the recombinant PD-ECGF antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Target Details for Thymidine Phosphorylase

Target: Thymidine Phosphorylase (TYMP)

Alternative Name: PD-ECGF

Background: Recognizes a protein (amino acid 482) of 55 kDa (in vivo 110 kDa homodimer), identified as platelet-derived endothelial growth factor (PD-ECGF), same as thymidine phosphorylase (TP) or gliostatin. In the presence of inorganic orthophosphate, it catalyzes the reversible phospholytic cleavage of thymidine and deoxyuridine to their corresponding bases and 2-deoxyribose-1-phosphate. It is both chemotactic and mitogenic for endothelial cells and a non-heparin binding angiogenic factor present in platelets. Its enzymatic activity is crucial for angiogenic activity (metabolite is angiogenic). Higher levels of serum TP/PD-ECGF are observed in cancer patients. It is also involved in transformation of fluoropyrimidines, cytotoxic agents used in the treatment of a variety of malignancies, into active cytotoxic metabolites (e.g. 5-deoxy-5-fluorouridine to 5-FU). High intra-cellular levels of TP/PD-ECGF are associated with increased chemosensitivity to such antimetabolites.

UniProt: P19971

Pathways: Signaling Events mediated by VEGFR1 and VEGFR2